INDIAN GENERIC DRUG MAKER DELVIN MAKES FORAY INTO MALAYSIA

By P.Vijian

CHENNAI, June 1 (Bernama) -- A Chennai-based generic drug maker is getting
ready to launch a range of drugs in the Malaysian pharmaceutical market this
July.

Delvin Formulations Pvt Ltd which is involved in research and development of
new drugs for the United States and regulated markets, is exploring new
opportunities in the growing Southeast Asian region.

"We are in the process of negotiating with a Malaysian distributor and will
finalise this by July.

"We will launch our oral disintegrant tablets that are good for paediatric
patients," J.Jayaseelan, managing director of Delvin told Bernama.

India has emerged as the world largest generic drug producer, chiefly
propelled by home-grown matured India pharmaceutical companies, boasting
exports worth US$7.41 billion (RM22.2 billion) last year.

India's exports to Asean markets stood at US$482 million (RM1.4 billion) in
2010.

"India has become a hub for drug manufacturing. We are producing cheap and
quality drugs for the global market. Delvin is trying to establish links in
Southeast Asia, like Malaysia and Singapore," added Jayaseelan.

The company has filed 10 ANDAs (application for new drug approval) with the
United States Food and Drug Administration with another eight in the
pipeline.

The Malaysian pharmaceutical sector, though yet to peak, is reportedly
growing at about eight percent annually and continues to attract foreign drug
makers.

"The Malaysian economy is doing very well. There is good scope for Indian
pharmaceutical companies that offer quality and cost effective drugs,"
Jayaseelan said.